Telisotuzumab vedotin
Non-small cell lung cancer
Phase 2Active
Key Facts
About AbbVie
AbbVie Inc. is a research-based biopharmaceutical company formed in 2013 as a spinoff from Abbott Laboratories. The company focuses on developing and delivering innovative therapies that address some of the world's most complex and serious diseases. With a strong portfolio led by immunology treatments and a growing oncology franchise, AbbVie has established itself as a leader in specialty therapeutics with global operations and a commitment to advancing patient care.
View full company profileTherapeutic Areas
Other Non-small cell lung cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| ANKTIVA® + Tislelizumab | ImmunityBio | Phase 3 |
| Pepinemab (VX15/2503) | Vaccinex | Phase 1/2 |